Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Bausch & Lomb Incorporated
Information provided by (Responsible Party):
Bausch & Lomb Incorporated Identifier:
First received: November 17, 2011
Last updated: February 13, 2015
Last verified: February 2015
The objective of this study is to compare the efficacy and safety of topical Loteprednol Etabonate (LE), 0.5%, to Prednisolone Acetate 1%, for the treatment of postoperative inflammation following ocular surgery for childhood cataract.

Condition Intervention Phase
Drug: Loteprednol etabonate
Drug: Prednisolones acetate
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Topical Loteprednol Etabonate 0.5%, Versus Prednisolone Acetate 1%, for the Treatment of Intraocular Inflammation Following Surgery for Childhood Cataract

Resource links provided by NLM:

Further study details as provided by Bausch & Lomb Incorporated:

Primary Outcome Measures:
  • Anterior Chamber Inflammation [ Time Frame: Postoperative Day 29 ] [ Designated as safety issue: No ]
    Mean grade of converted anterior chamber inflammation

Secondary Outcome Measures:
  • Anterior Chamber Cells & Flare [ Time Frame: Over all visits 42 days ] [ Designated as safety issue: No ]
    Proportion of subjects with anterior chamber inflammation.

Estimated Enrollment: 170
Study Start Date: July 2013
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Loteprednol etabonate
Loteprednol etabonate 0.5%
Drug: Loteprednol etabonate
1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
Active Comparator: Prednisolones acetate
Prednisolone acetate 1.0%
Drug: Prednisolones acetate
1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.


Ages Eligible for Study:   up to 11 Years   (Child)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is a candidate for routine, uncomplicated surgery for childhood cataract

Exclusion Criteria:

  • Subjects who have a severe/serious ocular condition, or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment or follow-up.
  • Subjects with glaucoma, ocular hypertension, or those receiving intraocular pressure (IOP) lowering therapy in either eye or systemically.
  • Subjects with a history of steroid-induced IOP elevation in either eye.
  • Subjects who have known hypersensitivity or other contraindication to the study drug(s) or any components in the drug formulation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01475643

Contact: Johnson Varughese 908-927-1162

United States, New York
Bausch & Lomb Inc Recruiting
Rochester, New York, United States, 14609
Sponsors and Collaborators
Bausch & Lomb Incorporated
Study Director: Johnson Varughese Valeant/Bausch & Lomb
  More Information

Responsible Party: Bausch & Lomb Incorporated Identifier: NCT01475643     History of Changes
Other Study ID Numbers: 670 
Study First Received: November 17, 2011
Last Updated: February 13, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Bausch & Lomb Incorporated:
Pediatric cataract

Additional relevant MeSH terms:
Pathologic Processes
Lens Diseases
Eye Diseases
Uveal Diseases
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone hemisuccinate
Prednisolone phosphate
Loteprednol Etabonate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents
Anti-Allergic Agents processed this record on January 17, 2017